Literature DB >> 17465944

Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 x 10(9) and 20 x 10(9) per L.

Shoshan Nevo1, Alice K Fuller, Eric Hartley, Mark E Borinsky, Georgia B Vogelsang.   

Abstract

BACKGROUND: Prophylactic platelet (PLT) transfusions are given as a standard care in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT). This retrospective analysis evaluates utilization of blood transfusions, risk of bleeding, and survival in 480 HSCT patients at 10 x 10(9) and 20 x 10(9) per L prophylactic trigger levels. STUDY DESIGN AND METHODS: A total of 224 patients received prophylactic PLT transfusions at 20 x 10(9) per L threshold (1997-1998, SP1); 256 patients had prophylaxis at 10 x 10(9) per L (1999-2001, SP2). Bleeding scores were assigned daily.
RESULTS: A slight reduction in PLT transfusions per patient in SP2 compared with SP1 was not statistically significant (odds ratio, 0.82; 95% confidence interval, 0.51-1.33; p = 0.416), yet a significantly higher proportion of patients in SP2 had PLT counts less than or equal to 10 x 10(9) per L compared to SP1 (p < 0.001). In patients who bled, however, there was no excess exposure to low PLT counts before bleeding started. A substantial number of patients who bled received PLT transfusions above the goal before bleeding started (82.9% in SP2, 41.5% in SP1) because of medical complications that associated with increased risk of bleeding. Bleeding incidence was similar in both study periods (21.9% in SP1, 16.4% in SP2; p = 0.526). Bleeding was significantly associated with reduced survival in both study periods.
CONCLUSIONS: Patients who bled were usually placed on a higher threshold before the onset of their major bleeding event and were not exposed to additional risk of bleeding from thrombocytopenia. Similarity in bleeding incidence between study periods appears to associate with adjustments to high-risk conditions and may not reflect consequences of the lower transfusion threshold.

Entities:  

Mesh:

Year:  2007        PMID: 17465944     DOI: 10.1111/j.1537-2995.2007.01193.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

1.  Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants.

Authors:  Melhem Solh; Claudio Brunstein; Shanna Morgan; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-14       Impact factor: 5.742

Review 2.  A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation.

Authors:  James L Gajewski; Viviana V Johnson; S Gerald Sandler; Antoine Sayegh; Thomas R Klumpp
Journal:  Blood       Date:  2008-06-26       Impact factor: 22.113

Review 3.  Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Authors:  Lise J Estcourt; Simon J Stanworth; Carolyn Doree; Sally Hopewell; Marialena Trivella; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2015-11-18

Review 4.  A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Authors:  Gemma L Crighton; Lise J Estcourt; Erica M Wood; Marialena Trivella; Carolyn Doree; Simon Stanworth
Journal:  Cochrane Database Syst Rev       Date:  2015-09-30

5.  Initial performance evaluation of the UniCel® DxH 800 Coulter® cellular analysis system.

Authors:  B D Hedley; M Keeney; I Chin-Yee; W Brown
Journal:  Int J Lab Hematol       Date:  2011-02       Impact factor: 2.877

Review 6.  Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Authors:  Lise J Estcourt; Simon Stanworth; Carolyn Doree; Marialena Trivella; Sally Hopewell; Patricia Blanco; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2015-10-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.